Literature DB >> 29477367

Dose-dependent toxicity of ipilimumab in metastatic melanoma.

Alexandra Olischewsky1, Sofie De Schrijver2, Agnes Bankfalvi3, Axel Wetter4, Lisa Zimmer5, Elisabeth Livingstone6, Dirk Schadendorf7, Selma Ugurel8.   

Abstract

Entities:  

Keywords:  Immune checkpoint inhibition; Ipilimumab; Melanoma; Toxicity

Mesh：

Substances：

Year:  2018        PMID： 29477367     DOI： 10.1016/j.ejca.2018.01.088

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  1 in total

1.  Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma.

Authors:  Paolo Antonio Ascierto; Michele Del Vecchio; Andrzej Mackiewicz; Caroline Robert; Vanna Chiarion-Sileni; Ana Arance; Céleste Lebbé; Inge Marie Svane; Catriona McNeil; Piotr Rutkowski; Carmen Loquai; Laurent Mortier; Omid Hamid; Lars Bastholt; Brigitte Dreno; Dirk Schadendorf; Claus Garbe; Marta Nyakas; Jean-Jacques Grob; Luc Thomas; Gabriella Liszkay; Michael Smylie; Christoph Hoeller; Virginia Ferraresi; Florent Grange; Ralf Gutzmer; Joanna Pikiel; Fareeda Hosein; Burcin Simsek; Michele Maio
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.